Aclaris Therapeutics Inc. (NASDAQ:ACRS) insider Kamil Ali-Jackson sold 1,841 shares of the company’s stock in a transaction dated Wednesday, September 28th. The stock was sold at an average price of $24.66, for a total value of $45,399.06. Following the completion of the sale, the insider now owns 77,798 shares in the company, valued at approximately $1,918,498.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Kamil Ali-Jackson also recently made the following trade(s):
- On Friday, August 26th, Kamil Ali-Jackson sold 3,738 shares of Aclaris Therapeutics stock. The stock was sold at an average price of $20.35, for a total value of $76,068.30.
Aclaris Therapeutics Inc. (NASDAQ:ACRS) opened at 25.61 on Monday. Aclaris Therapeutics Inc. has a 12 month low of $10.99 and a 12 month high of $33.88. The stock’s market cap is $548.44 million. The firm’s 50-day moving average price is $22.46 and its 200-day moving average price is $20.11.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Thursday, August 11th. The company reported ($0.62) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.01. On average, analysts predict that Aclaris Therapeutics Inc. will post ($2.60) earnings per share for the current year.
A number of brokerages have recently commented on ACRS. Zacks Investment Research downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. JMP Securities initiated coverage on Aclaris Therapeutics in a research note on Friday. They issued an “outperform” rating and a $34.00 target price on the stock. Guggenheim initiated coverage on Aclaris Therapeutics in a research report on Friday, June 10th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Jefferies Group increased their price target on Aclaris Therapeutics from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Friday, August 12th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $31.80.
Several hedge funds have recently bought and sold shares of ACRS. Nationwide Fund Advisors boosted its stake in Aclaris Therapeutics by 47.0% in the second quarter. Nationwide Fund Advisors now owns 5,747 shares of the company’s stock worth $106,000 after buying an additional 1,838 shares during the period. Tocqueville Asset Management L.P. bought a new position in shares of Aclaris Therapeutics during the second quarter valued at about $185,000. Teachers Advisors Inc. boosted its position in shares of Aclaris Therapeutics by 91.0% in the second quarter. Teachers Advisors Inc. now owns 14,212 shares of the company’s stock valued at $262,000 after buying an additional 6,772 shares during the period. Swiss National Bank bought a new position in shares of Aclaris Therapeutics during the second quarter valued at about $283,000. Finally, Sabby Management LLC bought a new position in shares of Aclaris Therapeutics during the second quarter valued at about $292,000. Institutional investors and hedge funds own 71.39% of the company’s stock.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.